| 1435 |
National Cancer Institute |
Html |
en |
Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood extracranial germ cell tumors. |
| testicular germ cell | 0.206027 |
| treatment | 0.243869 |
| germ cell tumors | 0.902772 |
| stage | 0.204984 |
| extracranial germ cell | 0.708761 |
|
| ovarian germ cell | 0.212137 |
| childhood extracranial germ | 0.398861 |
| cancer | 0.399843 |
| clinical trials | 0.265215 |
|
CLICK HERE |
| 1568 |
National Cancer Institute |
Html |
en |
Gastrointestinal Carcinoid Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of gastrointestinal carcinoid tumors. |
| carcinoid tumor cells | 0.278965 |
| metastatic GI carcinoid | 0.238039 |
| treatment | 0.556764 |
| cancer treatment | 0.277356 |
| malignant tumor cells | 0.240006 |
| general information | 0.281992 |
| GI carcinoid tumors | 0.692008 |
| Hormone therapy | 0.212489 |
| Lung Cancer Treatment | 0.223918 |
| NCI-supported cancer | 0.254433 |
| cancer cells | 0.281516 |
| stomach | 0.228344 |
| hepatic artery | 0.21097 |
| body | 0.300003 |
| type | 0.211866 |
| PDQ cancer information | 0.277061 |
| clinical trial search | 0.358585 |
| carcinoid tumor spreads | 0.266506 |
| treatment clinical trials | 0.240478 |
| recurrent GI carcinoid | 0.223511 |
| National Cancer Institute | 0.243506 |
| clinical trials | 0.834392 |
| tumor cells | 0.308788 |
|
| Carcinoid Tumors Treatment | 0.268829 |
| cancer information summary | 0.243151 |
| clinical trial | 0.501578 |
| new treatment | 0.293328 |
| Rectal Cancer Treatment | 0.224504 |
| liver | 0.203338 |
| gastrointestinal carcinoid tumor | 0.314953 |
| patients | 0.237822 |
| carcinoid heart syndrome | 0.215848 |
| carcinoid tumor tissue | 0.264996 |
| carcinoid syndrome | 0.334872 |
| metastatic tumor | 0.206035 |
| blood | 0.210445 |
| cancer clinical trials | 0.359168 |
| lymph nodes | 0.28707 |
| carcinoid tumors | 0.943574 |
| radiation therapy | 0.236209 |
| internal radiation therapy | 0.21238 |
| cancer | 0.673084 |
| information | 0.294151 |
| small intestine | 0.264836 |
| gastrointestinal carcinoid tumors | 0.573326 |
| Intestine Cancer Treatment | 0.236505 |
|
CLICK HERE |
| 1666 |
National Cancer Institute |
Html |
en |
Testicular Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for testicular cancer. |
| testicular self-exams | 0.545422 |
| ongoing clinical trials | 0.499986 |
| PDQ cancer information | 0.758311 |
| testicular cancer | 0.955987 |
| testicular germ cell | 0.59857 |
| testicular carcinoma | 0.546926 |
| NCI Web site | 0.507088 |
| testicular cancers | 0.553122 |
| clinical trials | 0.669739 |
| early detection | 0.495849 |
| germ cells | 0.505641 |
| cancer information summary | 0.64569 |
| clinical trial | 0.511819 |
| breast cancer prevention | 0.524202 |
| spermatic cord | 0.49407 |
| PDQ summaries | 0.534816 |
| cancer patients | 0.49191 |
| latest published information | 0.509374 |
| NCI’s PDQ | 0.538459 |
| cancer symptoms | 0.51215 |
| NCI PDQ cancer | 0.620022 |
| tests | 0.527688 |
| testicular cancer screening | 0.701295 |
| routine screening test | 0.519043 |
|
| PDQ Screening | 0.553678 |
| testicles | 0.486139 |
| screening tests | 0.48752 |
| Cancer Information Service | 0.545478 |
| common cancer | 0.501504 |
| male sex glands | 0.496865 |
| Prevention Editorial Board | 0.56412 |
| treatment clinical trials | 0.501604 |
| National Cancer Institute | 0.653794 |
| PDQ documents | 0.525451 |
| cancer doctors | 0.485997 |
| long coiled tube | 0.493438 |
| new treatment | 0.506259 |
| health professional version | 0.485461 |
| Cancer screening trials | 0.571582 |
| PDQ database | 0.532773 |
| Cancer Care page | 0.527585 |
| Testicular Cancer Treatment | 0.685082 |
| risk factor | 0.499445 |
| PDQ summary | 0.654344 |
| routine physical exam | 0.576949 |
| cancer information summaries | 0.554625 |
| health professional versions | 0.489301 |
| comprehensive cancer information | 0.555761 |
|
CLICK HERE |
| 1678 |
National Cancer Institute |
Html |
en |
Communication in Cancer Care (PDQ®)–Health Professional Version |
Effective cancer communication between the health care team, cancer patients, and their family is important. Learn about communication skills that support a patient-centered practice and how to talk with adults and children about their diagnosis, prognosis, and transition to end-of-life care in this expert-reviewed summary. |
| female breast cancer | 0.57505 |
| eligible patients | 0.564938 |
| bad news | 0.743613 |
| medical decision making | 0.58503 |
| physicians | 0.592367 |
| direct patient care | 0.564892 |
| diverse cancer patients | 0.603459 |
| clinical trials | 0.61877 |
| communication | 0.630971 |
| early-stage breast cancer | 0.592631 |
| patients cultural beliefs | 0.582353 |
| breast cancer experience | 0.564126 |
| breast cancer treatment | 0.579002 |
| breast cancer patients | 0.646574 |
| patients | 0.906881 |
| cancer patients | 0.64886 |
| white patients | 0.564203 |
| cancer diagnosis | 0.569139 |
| health care costs | 0.565569 |
| cancer patients report | 0.596785 |
| decision making | 0.744128 |
| breast cancer therapy | 0.566081 |
| treatment decision making | 0.568266 |
| older breast cancer | 0.566807 |
| care | 0.590659 |
|
| treatment | 0.626966 |
| American oncology patients | 0.58299 |
| study | 0.656108 |
| patient communication preferences | 0.600601 |
| cancer disclosure issues | 0.56732 |
| African American patients | 0.584216 |
| different information styles | 0.572854 |
| Asian American women | 0.565505 |
| patient decision making | 0.57769 |
| black patients | 0.564183 |
| younger patients | 0.563325 |
| high information needs | 0.57343 |
| health care | 0.579997 |
| patient information style | 0.59028 |
| older patients | 0.579527 |
| initial cancer diagnosis | 0.562722 |
| Cancer care | 0.562573 |
| breast cancer | 0.780881 |
| specific treatment information | 0.578443 |
| patient satisfaction | 0.579033 |
| information patients | 0.586119 |
| treatment options | 0.585641 |
| rural American patients | 0.584504 |
| pessimistic information people | 0.566128 |
|
CLICK HERE |
| 1858 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de glándulas salivales (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de glándulas salivales. |
| salivary gland carcinoma | 0.756611 |
| salivary neoplasms | 0.424559 |
| estroma linfoide | 0.413137 |
| prognostic factors | 0.41902 |
| gland tumours | 0.43032 |
| Spiro RH | 0.465562 |
| Sin embargo | 0.429856 |
| advanced salivary | 0.421758 |
| Malignant parotid tumors | 0.41189 |
| minor salivary | 0.423431 |
| tumores benignos | 0.597781 |
| Salivary Gland Disease | 0.423228 |
| tumores malignos mixtos | 0.484605 |
| botulinum toxin | 0.428989 |
| Radiat Oncol Biol | 0.471433 |
| glándulas salivales benignos | 0.570833 |
| neck neoplasia following | 0.437258 |
| fuerte predilección | 0.414088 |
| Parotid gland tumours | 0.420714 |
| salivary gland | 0.859636 |
| Head Neck Surg | 0.476609 |
| mucoepidermoid carcinoma | 0.597885 |
| gland malignant neoplasms | 0.445484 |
| tumores benignos mixtos | 0.438326 |
| único sÃntoma | 0.425265 |
|
| parotid gland | 0.431427 |
| lesiones carcinoma | 0.466113 |
| relativa frecuencia | 0.450675 |
| sección carcinoma | 0.486375 |
| carcinoma ex-tumor | 0.470245 |
| unresectable carcinomas | 0.426636 |
| Oral Oncol | 0.420027 |
| major salivary glands | 0.414421 |
| Otolaryngol Head Neck | 0.413034 |
| término carcinoma | 0.475993 |
| carcinoma epidermoide | 0.472012 |
| edad promedio | 0.670934 |
| Salivary Gland Tumours | 0.424182 |
| carcinoma with | 0.481329 |
| adenocarcinoma sai | 0.463524 |
| carcinoma salival basaloide | 0.481935 |
| carcinomas quÃsticos adenoides | 0.459095 |
| Botulinum toxin treatment | 0.413697 |
| with parotid carcinoma | 0.483397 |
| Oncol Biol Phys | 0.47266 |
| linfadenoma sebáceo | 0.417003 |
| elemento carcinoma | 0.475416 |
| carcinoma mucoepidermoide | 0.988653 |
| neoplasias benignas | 0.45166 |
|
CLICK HERE |
| 2039 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de piel (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar sistemáticamente el cáncer de piel. |
| skin cancer | 0.943888 |
| pediatric melanoma | 0.526248 |
| cutaneous melanoma | 0.524708 |
| incidence estimate | 0.432333 |
| pediatric melanoma mortality | 0.475024 |
| Waldmann A | 0.448643 |
| pruebas directas | 0.467472 |
| accessed october | 0.431704 |
| American Cancer Society | 0.752465 |
| largo plazo | 0.427741 |
| incidencia promedio | 0.427245 |
| Am Acad Dermatol | 0.559713 |
| Skin biopsy | 0.467836 |
| CA Cancer | 0.436346 |
| Preventive Services Task | 0.49324 |
| Melanoma mortality following | 0.47412 |
| Instituto Nacional | 0.477662 |
| diagnosing melanoma | 0.465782 |
| Melanoma Pathology Study | 0.472332 |
| PDQ Exámenes | 0.446099 |
| malignant skin tumors | 0.44617 |
| Skin biopsy utilization | 0.44782 |
| Estados Unidos | 0.486058 |
| study comparing trends | 0.42068 |
| Skin biopsy rates | 0.447638 |
|
| JAMA Dermatol | 0.430327 |
| US Preventive Services | 0.448303 |
| melanoma incidence among | 0.478575 |
| Nolte S | 0.427295 |
| Rogers HW | 0.427126 |
| consecuencias adversas | 0.434206 |
| Gandini S | 0.430629 |
| estudio screen | 0.45426 |
| United States | 0.464438 |
| Arch Dermatol | 0.504577 |
| Cancer Facts | 0.476716 |
| Weinstock MA | 0.509901 |
| National Cancer Institute | 0.43929 |
| Systematic skin | 0.44278 |
| population-based screening intervention | 0.428982 |
| Services Task Force | 0.491749 |
| radiación uv | 0.425917 |
| Dermatol Surg | 0.429711 |
| systematic review | 0.43149 |
| melanoma mortality | 0.579785 |
| BMC Cancer | 0.438009 |
| malignant melanoma | 0.574467 |
| nonmelanoma skin cancer | 0.673873 |
| Lott JP | 0.429356 |
|
CLICK HERE |
| 2063 |
National Cancer Institute |
Html |
es |
Radón y cáncer |
Hoja informativa acerca del radón, un gas radiactivo sin olor, y su posible asociación con el cáncer, y cómo realizar pruebas de detección del radón en el hogar. |
| residential radon case-control | 0.38371 |
| Health Risks | 0.326257 |
| residential radon | 0.683536 |
| elevada exposición | 0.322129 |
| American case-control studies | 0.325499 |
| Kansas State University | 0.319808 |
| lung cancer | 0.82038 |
| largo plazo | 0.437964 |
| Hill D | 0.332319 |
| Scandinavian Journal | 0.348044 |
| persons with lung | 0.339213 |
| Danish study | 0.316865 |
| Environmental Epidemiology | 0.320216 |
| Darby S | 0.336246 |
| collaborative analysis | 0.317051 |
| Environmental Health | 0.355768 |
| pequeñas partÃculas | 0.315096 |
| mundo inhala radón | 0.518177 |
| Lubin JH | 0.346614 |
| combined analysis | 0.316876 |
| Estados Unidos | 0.584661 |
| likely carcinogen | 0.314203 |
| Family From Radon | 0.368415 |
| elementos quÃmicos uranio | 0.332786 |
| PubMed Abstract | 0.939015 |
|
| Field RW | 0.336674 |
| altas concentraciones | 0.370467 |
| Cancer Journal | 0.333846 |
| Environmental Protection Agency | 0.326738 |
| National Radon Hotline | 0.369701 |
| Health Effects | 0.325858 |
| radón causa | 0.50069 |
| Public Health | 0.325273 |
| concentración promedio | 0.346248 |
| epidemiologic studies | 0.342525 |
| disponibles pruebas | 0.317342 |
| Exposure Analysis | 0.331287 |
| Health Physics | 0.355359 |
| BEIR VI | 0.314333 |
| gas radón | 0.662121 |
| Protecting Yourself | 0.31429 |
| corto plazo | 0.315556 |
| Residential radon gas | 0.389098 |
| risk among german | 0.327785 |
| persons without lung | 0.339772 |
| única forma | 0.341742 |
| Samet JM | 0.31548 |
| Retrieved October | 0.315338 |
| Zielinski JM | 0.315284 |
|
CLICK HERE |
| 3521 |
National Cancer Institute |
Html |
en |
NCI-MATCH Trial (Molecular Analysis for Therapy Choice) |
Information about the NCI-MATCH precision medicine trial, in which patients with advanced solid tumors and lymphomas are assigned to treatment arms based on the molecular profiles of their disease. |
| NCI-MATCH trial | 0.544063 |
| rare cancer | 0.541344 |
| COMET study | 0.578429 |
| genetic makeup | 0.540259 |
| trial | 0.805751 |
| clinical trial tracking | 0.631222 |
| usual genomic testing | 0.608947 |
| National Clinical Trials | 0.604691 |
| MATCH protocol summary | 0.637152 |
| treatment arms | 0.751732 |
| clinical trials | 0.747821 |
| newly enrolling patients | 0.642185 |
| MATCH trial | 0.634351 |
| health care professionals | 0.58508 |
| cancer care | 0.539135 |
| patients | 0.983397 |
| cancer patients | 0.598511 |
| tumor gene testing | 0.590848 |
| ECOG-ACRIN Cancer Research | 0.612355 |
| non-small cell lung | 0.606702 |
| objective response rate | 0.771639 |
| medicine cancer treatment | 0.706859 |
| genomic sequencing | 0.623041 |
| treatment arms address | 0.659842 |
|
| gene sequencing lab | 0.599434 |
| specific genetic change | 0.644953 |
| laboratory method | 0.524995 |
| Cancer Trials Support | 0.616424 |
| potential MATCH participants | 0.636971 |
| cancer cells | 0.549314 |
| common genetic changes | 0.635293 |
| Cancer Information Service | 0.610926 |
| clinical trial. | 0.538943 |
| genetic change | 0.741928 |
| adult trial groups | 0.623508 |
| health insurance company | 0.59001 |
| enrolled patients | 0.575046 |
| progression-free survival | 0.609538 |
| specific genetic changes | 0.64881 |
| NCI Community Oncology | 0.61311 |
| particular genetic change | 0.630183 |
| new tumor biopsy | 0.621774 |
| genetic changes | 0.811113 |
| MATCH treatment arm | 0.848463 |
| Caris Life Sciences | 0.607515 |
| NRG Oncology Group | 0.586136 |
| advanced solid tumors | 0.669501 |
| new clinical sites | 0.600949 |
|
CLICK HERE |
| 4300 |
National Cancer Institute |
Html |
en |
Cancer Moonshot℠ Blue Ribbon Panel |
The Blue Ribbon Panel Report outlines 10 recommendations to accelerate progress against cancer. The panel was established to ensure that the Cancer Moonshot's approaches are grounded in the best science. |
| BRP | 0.544911 |
| National Cancer Advisory | 0.917882 |
| pediatric cancer | 0.537601 |
| relevant scientific sectors | 0.512578 |
| Reduce cancer risk | 0.54942 |
| dynamic 3D maps | 0.479491 |
| early detection | 0.494934 |
| therapeutic targets | 0.493364 |
| presidentially appointed National | 0.528792 |
| new preclinical models | 0.493659 |
| national cancer data | 0.584851 |
| previously effective treatments | 0.485016 |
| early detection strategies | 0.482919 |
| new therapeutic targets | 0.480719 |
| cancer resistance | 0.471789 |
| E. Intensify research | 0.49241 |
| translational science network | 0.495254 |
| cancer technologies | 0.513048 |
| public idea submission | 0.473834 |
| broader cancer community | 0.579774 |
| transformative research recommendations | 0.554836 |
| cancer immunotherapy network | 0.593107 |
| Ribbon Panel report | 0.661804 |
| tumor evolution | 0.579883 |
|
| cancer health disparities | 0.557334 |
| final recommendations | 0.465114 |
| Cancer Immunology | 0.464811 |
| human tumor evolution | 0.504864 |
| specific recommendations | 0.466439 |
| cancer prevention | 0.548373 |
| C. Develop ways | 0.499508 |
| tumor profile data | 0.530939 |
| cancer cells | 0.472187 |
| group members | 0.429792 |
| Minimize cancer treatment | 0.561924 |
| direct patient involvement | 0.494413 |
| joint recommendations | 0.465939 |
| 3D cancer atlas | 0.546232 |
| multiple groups | 0.44011 |
| Cancer Moonshot Task | 0.60025 |
| Blue Ribbon Panel | 0.890429 |
| groups | 0.493987 |
| BRP members | 0.537843 |
| major topic areas | 0.508582 |
| Cancer Advisory Board | 0.925259 |
| efficient data analysis | 0.49446 |
| Develop new cancer | 0.562862 |
| future patient outcomes | 0.484191 |
|
CLICK HERE |
| 17294 |
National Cancer Institute |
Html |
es |
Anemia |
Información y consejos para controlar la anemia, un efecto secundario del tratamiento del cáncer.
|
| suficientes glóbulos | 0.941582 |
|
|
CLICK HERE |